CL2015001520A1 - Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares - Google Patents

Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares

Info

Publication number
CL2015001520A1
CL2015001520A1 CL2015001520A CL2015001520A CL2015001520A1 CL 2015001520 A1 CL2015001520 A1 CL 2015001520A1 CL 2015001520 A CL2015001520 A CL 2015001520A CL 2015001520 A CL2015001520 A CL 2015001520A CL 2015001520 A1 CL2015001520 A1 CL 2015001520A1
Authority
CL
Chile
Prior art keywords
slurp
protein
treatment
eye diseases
diseases
Prior art date
Application number
CL2015001520A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Marc Combette
Catherine Deloche
Claire Abadie
Julien Perino
Sebastien Mouz
Original Assignee
Brightpulse Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brightpulse Holding Ltd filed Critical Brightpulse Holding Ltd
Publication of CL2015001520A1 publication Critical patent/CL2015001520A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
CL2015001520A 2012-12-07 2015-06-04 Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares CL2015001520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12196007.4A EP2740485B1 (en) 2012-12-07 2012-12-07 Protein slurp-1 for use in the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
CL2015001520A1 true CL2015001520A1 (es) 2016-05-20

Family

ID=47297008

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001520A CL2015001520A1 (es) 2012-12-07 2015-06-04 Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares

Country Status (15)

Country Link
US (1) US10098925B2 (https=)
EP (1) EP2740485B1 (https=)
JP (1) JP6335188B2 (https=)
KR (1) KR20150108351A (https=)
CN (1) CN105188731B (https=)
AU (1) AU2013353957B2 (https=)
BR (1) BR112015013215A2 (https=)
CA (1) CA2891201A1 (https=)
CL (1) CL2015001520A1 (https=)
EA (1) EA201591095A1 (https=)
IL (1) IL239078A0 (https=)
MX (1) MX2015006779A (https=)
SG (2) SG10201705592YA (https=)
WO (1) WO2014087022A1 (https=)
ZA (1) ZA201503747B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
EP3689327B1 (fr) * 2019-01-24 2025-03-12 Organes Tissus Régénération Réparation Remplacement Composition pharmaceutique dans le traitement de lésions pulmonaires
CN114601915B (zh) * 2022-03-25 2023-04-07 四川大学华西医院 Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1257184B (it) 1992-12-22 1996-01-10 Applied Research Systems Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
AU2004229237B2 (en) * 2003-04-16 2009-06-04 Merck Serono Sa Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
CA2806143A1 (en) * 2010-07-30 2012-02-02 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H Drug delivery devices and growth factor formulations for accelerated wound healing
EP3848055A1 (en) * 2011-06-03 2021-07-14 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US9132193B2 (en) * 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
CA2890424C (en) * 2012-11-08 2020-11-17 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases

Also Published As

Publication number Publication date
IL239078A0 (en) 2015-07-30
EP2740485A1 (en) 2014-06-11
SG11201503658XA (en) 2015-06-29
CN105188731B (zh) 2019-02-05
SG10201705592YA (en) 2017-08-30
BR112015013215A2 (pt) 2018-02-06
CN105188731A (zh) 2015-12-23
CA2891201A1 (en) 2014-06-12
EP2740485B1 (en) 2018-10-31
ZA201503747B (en) 2016-03-30
AU2013353957A1 (en) 2015-05-28
US20150320831A1 (en) 2015-11-12
JP2016502558A (ja) 2016-01-28
EA201591095A1 (ru) 2015-11-30
KR20150108351A (ko) 2015-09-25
AU2013353957B2 (en) 2018-05-17
WO2014087022A1 (en) 2014-06-12
MX2015006779A (es) 2015-10-29
US10098925B2 (en) 2018-10-16
JP6335188B2 (ja) 2018-05-30

Similar Documents

Publication Publication Date Title
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
BR112015002768A2 (pt) uso de lente de contato no tratamento de uma condição oftalmológica
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
PT2877184T (pt) Composições e tratamento para doenças e distúrbios oculares
CL2015000061A1 (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
IL238432A0 (en) Methods and devices for the treatment of ocular diseases in human subjects
PT2760475T (pt) Proteínas de fusão para o tratamento de distúrbios metabólicos
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
EP2906208A4 (en) THERAPEUTIC TREATMENT
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
HUE068364T2 (hu) Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
IL229858B (en) Polypeptides and uses thereof for tratment of autoimmune disorders and infection
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
PT3016654T (pt) Ácido tauroursodeoxicólico (tudca) para utilização no tratamento de doenças neurodegenerativas
HUE045148T2 (hu) Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére